{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000076","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.966588+00:00","generated_at":"2026-05-16T12:44:51.276324+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Indivior CEO and CFO receive base salary increases effective Jan 1, 2026","bullets":["CEO Joseph Ciaffoni salary increased from $1,050,000 to $1,115,000.","CFO Ryan Preblick salary increased from $559,000 to $604,000.","Changes effective January 1, 2026, approved by Board on Dec 12, 2025.","Based on competitive market review and Compensation Committee recommendation."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000076","json":"https://secwatch.observer/filing/0001625297-25-000076.json","markdown":"https://secwatch.observer/filing/0001625297-25-000076.md","text":"https://secwatch.observer/filing/0001625297-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000076/0001625297-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000076/indv-20251212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:44:51.276324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}